Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Slow releasing nerve...

    Slow releasing nerve pain killer that can be delivered via nose developed

    Written by Hina Zahid Published On 2019-05-21T19:15:07+05:30  |  Updated On 23 Aug 2021 4:20 PM IST

    Drugs can be delivered in various ways such as orally or through injections depending on their intended action. But sometimes drugs administered this way may result in side effects as well. In order to minimise side effects, scientists have been exploring ways in which drugs can be delivered with greater precision.


    Now Indian scientists have developed a new nanotechnology-based drug which can be administered through the nose. They have found that when neuropathic drugs are encapsulated in nanoparticles and transported via the nasal route they can be more effective in curing nerve related pains.


    Neuropathic pain is often escalating pain that occurs due to injury or lesions in nerves. It can arise randomly and can last for minutes to days. This pain is often experienced by individuals suffering from arthritis, multiple sclerosis, diabetes, spondylitis and those who have undergone chemotherapy for cancer.


    Lamotrigine, commonly used drug to relieve neuropathic pain, has many side-effects like skin rashes when taken orally, besides having low retention in its target organ - brain.


    Researchers recommend delivering such drugs via nasal route over oral route or injections to avoid side effects. However, poor permeability of drugs across nasal layer is a major issue in delivering drugs via this route. A group of Indian researchers has now found a solution to this problem.





    Scientists first developed a nano drug formulation by precipitating lamotrigine with Poly lactic-co-glycolic acid (PLGA) polymer. The polymer was used as it slowly releases the encapsulated drug.

    For comparing the efficacy of this nano-drug formulation as well as aqueous solution of the drug in reaching brain, both were administered to rats either orally, by injection in vein or through nose. Scientists found that both the formulations were found in maximum amounts in gastro-intestinal tract when given orally and vis-à-vis in blood when injected in veins. The nano-drug formulation delivered via nasal route could reach brain in copious amounts as compared to its aqueous form that got accumulated in buccal cavity.

    Scientists believe that high permeability and small size of nano-drug formulation are the reason it was able to reach brain and that in greater amounts than the aqueous form.

    "The promising results of study done on rats suggest that the drug can be transported to brain via nasal route. Further pharmacokinetic studies need to be done. Scale up studies to optimize drug loaded on nanoparticles formulations need to be done. Formulating these nanoparticles in the form of nasal creams, gels or aerosols can provide an alternative approach and an outpatient OPD) option for patients," explained Dr. Shweta Dang, author of the study and Associate Professor at Jaypee Institute of Technology, Noida while talking to India Science Wire.

    The research results have been published in journal Drug Delivery and Translational Research. The researcher team included Kuldeep Nigam, Atinderpal Kaur, Reema Gabrani and Shweta Dang (Jaypee Institute of Technology); Amit Tyagi (Defence Research and Development Organization); Md Nematullah and Farah Khan (Jamia Hamdard University).

    By Dr. Aditi Jain

    India Science Wire

    diabetesinjurymultiple sclerosisNanotechnologynasal routenerve pain killerneuropathic drugsneuropathic painnose developedpain killerPoly lactic-co-glycolic acid

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Hina Zahid
    Hina Zahid
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok